产品
编 号：F742189
分子式：C98H171N37O26
分子量：2283.64
分子式：C98H171N37O26
分子量：2283.64
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 1039342-24-9
产品详情
生物活性：
MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease.
体内研究：
MMI-0100 (100 μM; 28 days) inhibits intimal hyperplasia in a mouse vein graft model.Animal Model:12-week-old C57Bl/6 wild type mice (intimal hyperplasia)
Dosage:100 μM
Administration:vein graft, 28 days
Result:Diminished wall thickness at all postoperative time points in vein grafts treated with MMI-0100, with a ratio of 2.6-fold thicker at 4 weeks, compared to 4.7-fold thicker at 4 weeks in control grafts.
体外研究：
Naphthofluorescein (compound 19) (0-10 μM; 24 hours) suppresses the HIF-1 reporter activity in a concentration-dependent manner. .MMI-0100 (0.25 and 0.5 mM; 24 hours) slightly increases cell proliferation in both cell types compared to control cells treated with 20 ng/ml TNF-α alone.MMI-0100 (1 mM) treatment also increases both EC (11%) and SMC (7%) proliferation as compared to control, this response is not as robust as that induced by treatment with 0.5 mM MMI-0100.MMI-0100 does not induce EC apoptosis at any dose.
MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease.
体内研究：
MMI-0100 (100 μM; 28 days) inhibits intimal hyperplasia in a mouse vein graft model.Animal Model:12-week-old C57Bl/6 wild type mice (intimal hyperplasia)
Dosage:100 μM
Administration:vein graft, 28 days
Result:Diminished wall thickness at all postoperative time points in vein grafts treated with MMI-0100, with a ratio of 2.6-fold thicker at 4 weeks, compared to 4.7-fold thicker at 4 weeks in control grafts.
体外研究：
Naphthofluorescein (compound 19) (0-10 μM; 24 hours) suppresses the HIF-1 reporter activity in a concentration-dependent manner. .MMI-0100 (0.25 and 0.5 mM; 24 hours) slightly increases cell proliferation in both cell types compared to control cells treated with 20 ng/ml TNF-α alone.MMI-0100 (1 mM) treatment also increases both EC (11%) and SMC (7%) proliferation as compared to control, this response is not as robust as that induced by treatment with 0.5 mM MMI-0100.MMI-0100 does not induce EC apoptosis at any dose.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备